Latest Posts
August 15, 2025
Hope on the Horizon: Breakthrough Phase 2 Results for Stargardt Disease Therapy
A groundbreaking Phase 2 trial has shown the first-ever vision improvements in people with Stargardt disease — a condition with no approved treatment. Nanoscope Therapeutics’ gene-agnostic MCO-010 therapy produced meaningful gains in vision without serious side effects, paving the way for a pivotal Phase 3 trial starting in 2025.